Home > Compound List > Product Information
Levosimendan_Molecular_structure_CAS_141505-33-1)
Click picture or here to close

Levosimendan

Catalog No. L5545 Name Sigma Aldrich
CAS Number 141505-33-1 Website http://www.sigmaaldrich.com
M. F. C14H12N6O Telephone 1-800-521-8956
M. W. 280.28468 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 798

SYNONYMS

IUPAC name
1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide
IUPAC Traditional name
levosimendan
Synonyms
(R)-Simendan
R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile
OR 1259
2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile
(-)-OR-1259

DATABASE IDS

MDL Number MFCD00867135
CAS Number 141505-33-1

PROPERTIES

Empirical Formula (Hill Notation) C14H12N6O
Purity ≥98% (HPLC)
Apperance yellow powder
Optical Rotation [α]/D -500 to -650°, c = 0.5 in THF
Solubility DMSO: ≥20 mg/mL
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H302-H312-H332
European Hazard Symbols Harmful Harmful (Xn)
MSDS Link Download
GHS Precautionary statements P280
Risk Statements 20/21/22
RTECS TY1570210
Safety Statements 36/37
Storage Temperature room temp
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
Description (简体中文)
Biochem/physiol Actions
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.

REFERENCES